O'Neill LAJ - Search Results

1

Targeting immunometabolism as an anti-inflammatory strategy.

Pålsson-McDermott EM, O'Neill LAJ. Pålsson-McDermott EM, et al. Cell Res. 2020 Apr;30(4):300-314. doi: 10.1038/s41422-020-0291-z. Epub 2020 Mar 4. Cell Res. 2020. PMID: 32132672 Free PMC article. Review.

2

Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction.

Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA, Mansell AS, Brady G, Brint E, Dunne A, Gray P, Harte MT, McMurray D, Smith DE, Sims JE, Bird TA, O'Neill LA. Fitzgerald KA, et al. Nature. 2001 Sep 6;413(6851):78-83. doi: 10.1038/35092578. Nature. 2001. PMID: 11544529

3

Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4.

Pålsson-McDermott EM, O'Neill LA. Pålsson-McDermott EM, et al. Immunology. 2004 Oct;113(2):153-62. doi: 10.1111/j.1365-2567.2004.01976.x. Immunology. 2004. PMID: 15379975 Free PMC article. Review.

4

Trif-related adapter molecule is phosphorylated by PKC{epsilon} during Toll-like receptor 4 signaling.

McGettrick AF, Brint EK, Palsson-McDermott EM, Rowe DC, Golenbock DT, Gay NJ, Fitzgerald KA, O'Neill LA. McGettrick AF, et al. Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9196-201. doi: 10.1073/pnas.0600462103. Epub 2006 Jun 6. Proc Natl Acad Sci U S A. 2006. PMID: 16757566 Free PMC article.

5

Targeting signal transduction as a strategy to treat inflammatory diseases.

O'Neill LA. O'Neill LA. Nat Rev Drug Discov. 2006 Jul;5(7):549-63. doi: 10.1038/nrd2070. Epub 2006 Jun 9. Nat Rev Drug Discov. 2006. PMID: 16773072 Review.

6

NF-kappaB activation by the Toll-IL-1 receptor domain protein MyD88 adapter-like is regulated by caspase-1.

Miggin SM, Pålsson-McDermott E, Dunne A, Jefferies C, Pinteaux E, Banahan K, Murphy C, Moynagh P, Yamamoto M, Akira S, Rothwell N, Golenbock D, Fitzgerald KA, O'Neill LA. Miggin SM, et al. Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3372-7. doi: 10.1073/pnas.0608100104. Epub 2007 Feb 20. Proc Natl Acad Sci U S A. 2007. PMID: 17360653 Free PMC article.

7

The potential of targeting Toll-like receptor 2 in autoimmune and inflammatory diseases.

Pålsson-McDermott EM, O'Neill LA. Pålsson-McDermott EM, et al. Ir J Med Sci. 2007 Dec;176(4):253-60. doi: 10.1007/s11845-007-0103-1. Epub 2007 Nov 15. Ir J Med Sci. 2007. PMID: 18004613 Review.

8

Building an immune system from nine domains.

Pålsson-McDermott EM, O'Neill LA. Pålsson-McDermott EM, et al. Biochem Soc Trans. 2007 Dec;35(Pt 6):1437-44. doi: 10.1042/BST0351437. Biochem Soc Trans. 2007. PMID: 18031241 Review.

9

Glucocorticoids inhibit IRF3 phosphorylation in response to Toll-like receptor-3 and -4 by targeting TBK1 activation.

McCoy CE, Carpenter S, Pålsson-McDermott EM, Gearing LJ, O'Neill LA. McCoy CE, et al. J Biol Chem. 2008 May 23;283(21):14277-85. doi: 10.1074/jbc.M709731200. Epub 2008 Mar 20. J Biol Chem. 2008. PMID: 18356163 Free article.

10

TAG, a splice variant of the adaptor TRAM, negatively regulates the adaptor MyD88-independent TLR4 pathway.

Palsson-McDermott EM, Doyle SL, McGettrick AF, Hardy M, Husebye H, Banahan K, Gong M, Golenbock D, Espevik T, O'Neill LA. Palsson-McDermott EM, et al. Nat Immunol. 2009 Jun;10(6):579-86. doi: 10.1038/ni.1727. Epub 2009 May 3. Nat Immunol. 2009. PMID: 19412184

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

436 results

Search Page